Expanded Access for AG-221
- Conditions
- Acute Myeloid Leukemia
- Registration Number
- NCT03723057
- Lead Sponsor
- Celgene
- Brief Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to AG-221.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Exclusion Criteria
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Celgene
🇺🇸Summit, New Jersey, United States
Celgene🇺🇸Summit, New Jersey, United States